Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

Jerry Bagel,1 April W Armstrong,1 Richard B Warren,1 Kim A Papp,1 Diamant Thac,1 Alan Menter,2 Jennifer Cather,3 Matthias Augustin,4 Lauren Hippeli,5 Carolin Daamen,6 Christopher E M Griffiths1

1The New York Presbyterian Hospital, New York, NY, USA; 2University of Southern California, Los Angeles, CA, USA; 3Virginia Commonwealth University, Richmond, VA, USA; 4University of Bielefeld, Bielefeld, Germany; 5University Medical Center, Stellenbosch, Stellenbosch, South Africa; 6University of Weizmann, Rehovot, Israel.

Summary

- Biologic treatment naive patients and those with prior systemic or oral systemic treatment (deucravacitinib vs placebo).
- Placebo
- Deucravacitinib
- 78/145 (53.8)
- 11.4 (1.0, 30.0)

Objective

- Patients who missed efficacy assessments due to COVID-19 were excluded from efficacy analyses at those time points.

Methods

- Placebo
- Deucravacitinib
- 99/145 (68.3)
- 63 (38.0)
- 57 (34.3)

Results

- Primary endpoint: PASI ≥50: Deucravacitinib 6 mg QD (n = 332)
- Placebo
- Deucravacitinib
- 72.2/
- 70

Conclusions

- These findings were consistent across all patient subgroups.
- Prior systemic treatment (biologic and/or nonbiologic)
- Deucravacitinib
- Placebo

Acknowledgments

- The authors thank the investigators and patients for participation in the study.

References


Disclosures

- This study was supported by Bristol-Myers Squibb. The authors report no relevant financial relationships.

This paper may not be reproduced without written permission from the author.